Ghassan Abou-Alfa on a paper by Arndt Vogel et al.

Ghassan Abou-Alfa, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on X:

“Final firm proof of pemigatinib open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 at ESMO Open.

Great international and successfully led teamwork of Memorial Sloan Kettering Cancer.”

Read further
Source: Ghassan Abou-Alfa/X